ERBB2 and breast cancer: Finally, based on the upregulation of YAP1/TAZ expression after trastuzumab treatment, we investigated the clinical significance of YAP1/TAZ expression on acquired trastuzumab resistance in metastatic HER2-positive breast cancer patients.